Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) CFO Alan Fuhrman acquired 9,500 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now owns 12,849 shares of the company's stock, valued at $205,584. This represents a 200.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Tyra Biosciences Price Performance

NASDAQ:TYRA traded down $0.29 during midday trading on Friday, reaching $16.39. The stock had a trading volume of 523,644 shares, compared to its average volume of 539,825. The stock has a market capitalization of $865.56 million, a P/E ratio of -9.70 and a beta of 1.08. Tyra Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $29.60. The firm's fifty day simple moving average is $22.39 and its 200-day simple moving average is $19.88.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TYRA shares. Oppenheimer increased their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a report on Thursday, September 19th. Wedbush restated an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price objective for the company. HC Wainwright raised their target price on Tyra Biosciences from $30.00 to $32.00 and gave the company a "buy" rating in a report on Monday, October 28th. Finally, Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $31.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TYRA. HighVista Strategies LLC bought a new position in shares of Tyra Biosciences during the 2nd quarter worth about $257,000. SG Americas Securities LLC bought a new position in Tyra Biosciences during the third quarter valued at about $311,000. Rhumbline Advisers raised its holdings in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock valued at $377,000 after acquiring an additional 2,574 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock worth $929,000 after acquiring an additional 14,352 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $977,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.